| Previous Close | 23.99 |
| Open | 23.80 |
| Bid | 22.65 x 900 |
| Ask | 24.00 x 1000 |
| Day's Range | 22.81 - 24.26 |
| 52 Week Range | 12.19 - 27.55 |
| Volume | 457,743 |
| Avg. Volume | 887,749 |
| Market Cap | 1.068B |
| Beta (3Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Deal Showcases the Potential of Peptelligence® as the "Gold Standard" Technology for Developing Oral Formulations of Peptide-Based Drugs Oral KORSUVA™ is Currently the Subject of Three Separate ...
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to Enteris’ Peptelligence® Technology. “We are pleased to take another important step in advancing Oral KORSUVA™ as a potential novel treatment for chronic pruritus by entering into this commercial formulation license,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
STAMFORD, Conn., July 31, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
STAMFORD, Conn., July 29, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical.
STAMFORD, Conn., July 24, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical.
Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In addition, Cara Therapeutics expects to grant certain of the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Study now fully enrolled; topline data expected in 4Q 2019 - STAMFORD, Conn., July 22, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on.
Oral KORSUVA is now the subject of three separate, ongoing Phase 2 clinical trials BOONTON, N.J. , July 11, 2019 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative ...
STAMFORD, Conn., July 09, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC).
STAMFORD, Conn., May 31, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo.
STAMFORD, Conn., May 08, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., May 07, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and.
STAMFORD, Conn., April 30, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
HENDERSON, NV / ACCESSWIRE / April 16, 2019 / CBD is becoming a household name in the US. In a recent survey conducted with the Harris Poll, Quartz asked over 2,000 Americans about their use and perceptions ...
NEW YORK, NY / ACCESSWIRE / April 11, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors. Traders News Source has created a comprehensive report on the current state of the cannabis market, including an outlook on where the industry may be headed in 2019. This report is a must read for investors in cannabis stocks.
STAMFORD, Conn., April 02, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / March 22, 2019 / Many high-profile companies in the cannabis market have posted incredible gains since start of 2019 and this trend looks to continue. The race to profit from ...
CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The marijuana stock market has seen an impressive couple months thus far in 2019, despite the cannabis industry still very much in its infancy. Especially in the cannabis sector, there is a considerable amount of smaller companies taking innovative approaches to create cannabis products, ultimately resulting in growing excitement from investors. Leafbuyer Technologies Inc (OTC:LBUY), Tauriga Sciences Inc (TAUG), Cara Therapeutics Inc (CARA), and HEXO Corp (NYSE American: HEXO, TSX: HEXO) are 4 marijuana stocks getting a boost from today's headlines.
STAMFORD, Conn., March 12, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
HENDERSON, NV / ACCESSWIRE / March 12, 2019 / Year to date, the Global Cannabis Stock Index is up almost 50% in less than three months. It's safe to say investors are bullish on the cannabis. Here are ...
STAMFORD, Conn., March 05, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.